Epithelial Ovarian Cancer, Fallopian Tube or Peritoneum, PARP Inhibitor
Conditions
Brief summary
With the widespread use of PARP inhibitors (PARPi) as maintenance therapy in ovarian cancer, there is still a lack of real-world data from large samples regarding their impact on survival outcomes in advanced and recurrent ovarian cancer. This study aims to conduct a pragmatic cohort study to evaluate the impact of first-line and second-line maintenance treatment with PARPi on survival rates in patients with advanced and recurrent ovarian cancer. The genetic status, different PARPi drugs, and the use of anti-angiogenic inhibitor maintenance therapy or not is used as confounding factors.
Interventions
None listed
Sponsors
Institute for Ovarian Cancer, Fudan University; Department of Gynecologic Oncology, Cancer Center, Fudan University Zhongshan Hospital, Shanghai, China
Department of Gynecologic Oncology, Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital), Hangzhou, China
Department of Gynecologic Oncology, State Key Laboratory of Oncology in South China, Collaborative Innovation Centre for Cancer Medicine, Sun Yat-sen University
Department of Gynecologic Oncology, Fudan University Cancer Hospital, Shanghai, China
Shanghai Gynecologic Oncology Group
Study design
Observational model
COHORT
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
FEMALE
Age
18 Years to 80 Years
Healthy volunteers
No
Inclusion criteria
Group 1: * Patients newly diagnosed with stage IIIC or IV primary epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer between December 2013 and December 2024. * Complete data on first-line treatment and maintenance therapy. * Availability of follow-up data. Group 2: * Patients with platinum-sensitive first recurrence of any stage of epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer, diagnosed between December 2013 and December 2024. * Disease progression occurring at least 6 months after the completion of the last platinum-based chemotherapy regimen. * Complete data on second-line treatment and maintenance therapy. * Availability of follow-up data.
Exclusion criteria
Group 1: * Non-epithelial tumors, borderline tumors, clear cell carcinoma, mucinous carcinoma. * Missing first-line or follow-up data. Group 2: * Non-epithelial tumors, borderline tumors, clear cell carcinoma, mucinous carcinoma. * Patients with second relapse. * Platinum-resistant patients, such as those who had disease progression during chemotherapy or within 6 months after platinum-based chemotherapy. * Missing second-line or follow-up data.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Overall Mortality | 11 years | Mortality of any cause |
Outcome results
None listed